microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Grace T Y KwokJing Ting ZhaoAnthony R GloverAnthony J GillRoderick Clifton-BlighBruce G RobinsonJulian C Y IpStan B SidhuPublished in: The oncologist (2019)
Adrenocortical carcinoma (ACC) is a rare endocrine cancer with outcomes not improving despite extensive research and new targeted therapies. Mitotane and etoposide/doxorubicin/cisplatin chemotherapy is trial validated for improved recurrence-free survival. However, a minority of patients experience sustained benefit. Significant side effects exist for this regimen, with patients often unable to attain target drug doses shown to give survival benefit. This preclinical study examines the role of microRNAs in sensitizing ACC to doxorubicin or mitotane. This study offers an important bridge between new and existing cancer treatments, offering an imminently translatable approach to the treatment of adrenocortical carcinoma.
Keyphrases
- free survival
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- stem cells
- type diabetes
- drug delivery
- radiation therapy
- patient reported outcomes
- study protocol
- adipose tissue
- mesenchymal stem cells
- lymph node metastasis
- open label
- insulin resistance
- adverse drug
- combination therapy
- glycemic control